Post–allo-HCT treatment options for relapsed HL
| Reference . | Year of publication . | No. of patients . | Combination administered . | ORR (%) . | Median PFS (mo) . | Median OS (mo) . | OS (%) . | GVHD rate (%) . |
|---|---|---|---|---|---|---|---|---|
| This study | 2016 | 20 | Nivolumab alone | 95 | Not reached | Not reached | 78 at 16 mo | 30 |
| 19 | 2013 | 4 | DLI + brentuximab vedotin | 100 | 11.5 | 1 death (sepsis and GVHD) | 75 | |
| 20 | 2016 | 16 | brentuximab vedotin with or without DLI (10 patients) | 69 | 6 | 3 deaths | 31 | |
| 21 | 2015 | 16 | brentuximab vedotin alone up to 16 cycles | 69 | 7 | 25 | 61 at 2 y | |
| 22 | 2014 | 18 | Bendamustine with or without DLI (50%) | 55 | 6 | 11 | 50 at 4 y | 67 (6 patients) |
| 23 | 2012 | 27 | DLI with or without chemotherapy | 37 | 7.5 | 14 | 20 at 4 y | 82 (100% in responders) |
| 24 | 2011 | 24 | DLI with or without chemotherapy (10 patients) | 79 | 18 | Not reached at 48 months | 59 at 4 y | 100 in responders |
| 25 | 2014 | 22 (33% of whole cohort) | Bendamustine alone | 57 | 10 | 7 in non responders | 70 at 1 y | Not reported |
| Reference . | Year of publication . | No. of patients . | Combination administered . | ORR (%) . | Median PFS (mo) . | Median OS (mo) . | OS (%) . | GVHD rate (%) . |
|---|---|---|---|---|---|---|---|---|
| This study | 2016 | 20 | Nivolumab alone | 95 | Not reached | Not reached | 78 at 16 mo | 30 |
| 19 | 2013 | 4 | DLI + brentuximab vedotin | 100 | 11.5 | 1 death (sepsis and GVHD) | 75 | |
| 20 | 2016 | 16 | brentuximab vedotin with or without DLI (10 patients) | 69 | 6 | 3 deaths | 31 | |
| 21 | 2015 | 16 | brentuximab vedotin alone up to 16 cycles | 69 | 7 | 25 | 61 at 2 y | |
| 22 | 2014 | 18 | Bendamustine with or without DLI (50%) | 55 | 6 | 11 | 50 at 4 y | 67 (6 patients) |
| 23 | 2012 | 27 | DLI with or without chemotherapy | 37 | 7.5 | 14 | 20 at 4 y | 82 (100% in responders) |
| 24 | 2011 | 24 | DLI with or without chemotherapy (10 patients) | 79 | 18 | Not reached at 48 months | 59 at 4 y | 100 in responders |
| 25 | 2014 | 22 (33% of whole cohort) | Bendamustine alone | 57 | 10 | 7 in non responders | 70 at 1 y | Not reported |
DLI, donor lymphocyte infusion; ORR, overall response rate.